Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients

Fardet, L.; Dupuy, Alain; Kérob, Delphine; Levy, Amit; Allez, Matthieu; Bégon, É.; Bachelez, Hervé; Morel, Patrice; Lebbe, Célèste

doi:10.1016/j.jaad.2006.07.027

Cited by 120 publications

(71 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 Case reports and series of cases have suggested that infliximab may be an effective treatment for HS, although the drug has yet to be approved for this purpose. [6][7][8][9][10] In the case reported here, the patient is female and the condition began at puberty and was confined exclusively to the inframammary region. The treatment proposed was the systemic use of sulfamethoxazole-trimethoprim with a maintenance dose and gradual withdrawal, in addition to topical antibiotics.…”

Section: Discussionmentioning

confidence: 77%

Caso para diagnóstico

Vasconcelos

Fonseca

Obadia

2011

An. Bras. Dermatol.

View full text Add to dashboard Cite

A hidradenite é uma inflamação crônica e supurativa das glândulas apócrinas. Ocorre mais frequentemente, nas mulheres, iniciando durante ou após a puberdade. Os locais mais acometidos são as axilas, porém, outras regiões ricas em glândulas apócrinas, podem ser comprometidas. A localização intermamária, de forma exclusiva, é rara e não encontramos relatos de outros casos semelhantes. Sua etiologia ainda não foi completamente elucidada

show abstract

Section: Discussionmentioning

confidence: 77%

Caso para diagnóstico

Vasconcelos

Fonseca

Obadia

2011

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…Case-series of patients denoted a promising perspective (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17). Only three prospective, open-label, non-randomized studies have been published; one involving the administration of infliximab in 10 patients (18) and two involving the administration of etanercept in 10 and 15 patients, respectively (4,19).…”

Section: Discussionmentioning

confidence: 99%

Long‐term efficacy of etanercept in hidradenitis suppurativa: results from an open‐label phase II prospective trial

Πελεκάνου

Kanni

Savva

et al. 2010

Experimental Dermatology

View full text Add to dashboard Cite

Objective: To evaluate the long-term efficacy of etanercept for the management of hidradenitis suppurativa.Methods: Analysis was based on the long-term follow-up (weeks 24-144) of 10 patients enrolled in a prospective open-label phase II study; etanercept was initially administered subcutaneously 50 mg once weekly for 12 weeks in 10 patients. Disease recurrence and the need to restart etanercept were recorded.Results: Three patients did not report any disease recurrence. A second course of treatment with etanercept was needed in seven patients. Favourable responses were found in five; two patients failed treatment. Conclusions:The first treatment course achieved long-term disease remission in almost one-third of patients. The remaining needed a second treatment course but even in that case, their disease severity at restart was significantly lower compared with baseline.

show abstract

“…The treatment of Hidradenitis suppurativa consists of topical antibacterial or antiseptic solutions, systemic antibiotics, steroids, hormonal therapy, anti-tumor necrosis factor and various surgical procedures [5,[15][16][17]. Although medical treatments are used in early stages of the disease, surgical treatment options are almost always the final definitive treatment method.…”

Section: Introductionmentioning

confidence: 99%

Reconstructive options in severe cases of Hidradenitis suppurativa

et al. 2010

View full text Add to dashboard Cite

AbstractHidradenitis suppurativa is a chronic, debilitating inflammatory disease of apocrine glands characterized with abscesses and nodular lesions. The treatment of Hidradenitis suppurativa consists of topical antibacterial or antiseptic solutions, systemic antibiotics, steroids, hormonal therapy, anti-tumor necrosis factor, and various surgical procedures. In this report, we present a series of 14 cases with severe Hidradenitis suppurativa. Surgical options are reviewed to show the best outcomes in the long term. A total of 14 patients (9 female, 5 male) were treated for advanced cases of Hidradenitis suppurativa. They underwent excision of the affected regions followed by reconstruction. The reconstruction methods consisted of split-thickness skin grafting and various cutaneous and myocutaneous flaps. There was no flap necrosis or dehiscence. One patient developed contracture in the axilla, for which he underwent release surgery. There were recurrences in 4 cases. There was no limitation of the arm movements in cases with flap reconstruction. In the long-term, they were satisfied with the results. In conclusion, incision and drainage should be avoided because it is of limited value. Surgical removal of the involved tissue should be the first treatment of choice. Depending on the defect following excision, local flaps should be preferred over the grafts for recurrence prevention.

show abstract

Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients

Cited by 120 publications

References 40 publications

Caso para diagnóstico

Caso para diagnóstico

Long‐term efficacy of etanercept in hidradenitis suppurativa: results from an open‐label phase II prospective trial

Reconstructive options in severe cases of Hidradenitis suppurativa

Contact Info

Product

Resources

About